Trial intelligence / Profile preview

Phase 3b treatment optimization study of oral asciminib in CML-CP after ≥2 prior TKIs

2020-006057-21Phase 3Active

Sponsor

Novartis

Start

Jul 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1